Journey Medical (DERM) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Journey Medical (DERM) over the past year, losing 38.0% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -88.5% for UNCY. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $93.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | UNCY |
|---|---|---|
| Share price | $3.30 | $3.35 |
| Market cap | $93.16M | $97.77M |
| 1-day change | -7.04% | -5.10% |
| YTD return | -57.20% | -41.94% |
| 1-year return | -55.76% | -37.96% |
| 5-year return | -61.13% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-0.18 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | — |
| Revenue growth (YoY) | +10.20% | — |
| Net income (latest FY) | $-11.43M | $-26.55M |
| Gross margin | 66.17% | — |
| Operating margin | -13.21% | — |
| Net margin | -18.48% | — |
| 52-week high | $9.56 | $8.74 |
| 52-week low | $3.21 | $3.33 |
| Distance from 52-week high | -65.46% | -61.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +286.36% | +685.07% |
| Average volume | 190.39K | 963.80K |
| Shares outstanding | 22.23M | 29.18M |
| Employees | 58 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed DERM by 17.8 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
DERM vs UNCY FAQ
Which is bigger, Journey Medical or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $93.16M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or UNCY?
UNCY returned -37.96% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.